Christopher O. Barnes

This study tracks the development of human autoantibodies against interferons over time, revealing their maturation, specificity, and synergistic effects in blocking IFN signaling.

This study shows that structure-guided vaccination can elicit broadly neutralizing antibodies targeting the HIV-1 silent face, expanding vaccine strategies.

This study identifies and characterizes human monoclonal antibodies targeting conserved coronavirus spike S2 epitopes, revealing distinct antiviral functions and Fc-dependent protective mechanisms.

This study identifies hr2.016, a potent and broad SARS-CoV-2 neutralizing antibody, and shows its neutralization depends on kinetic stability and avidity.

This study identifies two antibodies that recognize conserved SARS-CoV-2 RBD epitopes, revealing structural mechanisms for broad neutralization and escape pathways.

The paper identifies a disrupted CCR5-like immunoglobulin gene in black-footed ferrets linked to increased susceptibility to plague caused by Yersinia pestis.

The paper identifies two human monoclonal antibodies that neutralize West Nile virus and related orthoflaviruses, offering potential for antibody-based interventions.

This study identifies mAbs targeting HCoV-HKU1 spike protein and shows that receptor-binding site recognition alone does not predict neutralization in primary cells.

The paper designs native-like HIV Env single-chain trimers (SCTs) that are stable, immunogenic, and compatible with vaccine delivery methods.

This study shows sustained delivery of multivalent influenza vaccines via polymer-nanoparticle hydrogels enhances rapid, consistent, and broad humoral immunity against homologous and heterologous strains.

The paper designs bispecific antibodies that retain neutralization activity against multiple SARS-CoV-2 variants, including Omicron subvariants.

The paper identifies an antibody response against Staphylococcus epidermidis and shows how it can be engineered for therapeutic vaccination.

The paper detects and characterizes the SARS-CoV-2 lineage B.1.526 in New York, showing its rapid growth and potential impact on neutralization.

The paper classifies neutralizing antibodies against SARS-CoV-2 spike RBD based on structure, identifying binding modes and implications for vaccine and therapeutic strategies.